Two medicines, side by side
Abaloparatide vs romosozumab
Abaloparatide is labeled for osteoporosis; romosozumab has no indication this site maps. Their labels share no use, so they are not alternatives to each other. Only the romosozumab label carries a boxed warning.
Check it at the source: the abaloparatide FDA label on DailyMed (effective August 11, 2026); the romosozumab FDA label on DailyMed (effective July 16, 2026).
Highlights of the abaloparatide record
Abaloparatide (Tymlos) · label of August 11, 2026
Used for
From the label: indicationsTYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. […]
On the market
- Earliest approval on file
- April 28, 2017
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the romosozumab record
Romosozumab (Evenity) · label of July 16, 2026
POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE AND CARDIOVASCULAR DEATH EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death [see Warnings and Precautions (5.1) ]. EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors.
Used for
From the label: indicationsEVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1 ) Limitations of Use: Limit duration of use to 12 monthly doses. […]
On the market
- Earliest approval on file
- n/a
- Generic labelers
- none listed
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Source: FDA drug labels via openFDA (Abaloparatide label of August 11, 2026, Romosozumab label of July 16, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do abaloparatide and romosozumab differ on the record?
Only the romosozumab label carries a boxed warning.
How each works, in its label's words: Abaloparatide, “Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R).”; Romosozumab, “EVENITY inhibits the action of sclerostin, a regulatory factor in bone metabolism.”
| Abaloparatide | Romosozumab | |
|---|---|---|
| Labeled for | Osteoporosis | n/a |
| Pharmacologic class | Parathyroid Hormone-Related Peptide Analog | n/a |
| How it works (label) | Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. | EVENITY inhibits the action of sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. |
| Half-life (label) | n/a | n/a |
| Earliest approval on file (Drugs@FDA) | April 28, 2017 | n/a |
| First generic approved | none | none |
| Generic labelers (NDC) | none listed | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | n/a |
| 12-month price change | n/a | n/a |
| Boxed warning | No | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 29,258 | 13,496 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to abaloparatide
- every medicine labeled for the same conditions